Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venticute in Severe Pneumonia or Aspiration-Induced ARDS
NCT00074906Phase 3Completed
- Sponsor
- Takeda
- Start
- Nov 2003
- Primary completion
- Mar 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial of lusupultide in pneumonia, aspiration of gastric contents and acute respiratory distress syndrome (ARDS) (2 arms), sponsored by Takeda. Primary endpoint: Survival on day 28. Started Nov 2003; status: completed.
02
Drugs
lusupultide
03
Conditions
pneumoniaaspiration of gastric contentsacute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT00074906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00074906.